|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Shaheed Beheshti Medical University |
|---|---|
| Information provided by: | Shaheed Beheshti Medical University |
| ClinicalTrials.gov Identifier: | NCT00893854 |
Purpose
Cystoids macular edema (CME) is one of the most common causes of low vision due to uveitis. The treatment for reducing the intra-ocular inflammation can decrease the macular edema. In some patients, CME persists even after inflammation control, and additional treatment is needed for better vision. Oral steroid, periocular and intravitreal Triamcinolone are the principles in treatment, but some complications like cataracts and increased ocular pressure have been seen. Diclophenac is a non-steroid anti-inflammatory drug that improves the vision and decreases the macular thickness by slowing down the prostaglandin E2 (PGE2) ending in vascular endothelial growth factor (VEGF) inhibition. In this study, the investigators are going to compare the therapeutic affect of intravitreal Diclophenac and Triamcinolone in persistent uveitic cystoids macular edema. Since diclophenac is a cheap and accessible drug in all curative centers it could be applied instead of Triamcinolone.
| Condition | Intervention | Phase |
|---|---|---|
|
Uveitis Cystoid Macular Edema |
Drug: Diclophenac Drug: Triamcinolone |
Phase I |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Parallel Assignment |
| Official Title: | The Comparison Between the Therapeutic Affect of Intravitreal Diclophenac and Triamcinolone in Persistent Uveitic Cystoids Macular Edema |
| Arms | Assigned Interventions |
|---|---|
| Diclophenac: Experimental | Drug: Diclophenac |
| Triamcinolone: Experimental | Drug: Triamcinolone |
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Iran, Islamic Republic of | |
| Ophthalmic Research Center | Recruiting |
| Tehran, Iran, Islamic Republic of, 166666 | |
| Contact: Masoud Soheilian, MD +98 21 22585952 labbafi@hotmail.com | |
More Information
| Study ID Numbers: | 8727 |
| Study First Received: | May 4, 2009 |
| Last Updated: | May 4, 2009 |
| ClinicalTrials.gov Identifier: | NCT00893854 History of Changes |
| Health Authority: | Iran: Ethics Committee |
|
Anti-Inflammatory Agents Immunologic Factors Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists Edema Hormones Triamcinolone hexacetonide Signs and Symptoms Macular Edema Triamcinolone Acetonide Uveitis Sensory System Agents Therapeutic Uses Triamcinolone |
Anti-Inflammatory Agents, Non-Steroidal Analgesics Retinal Diseases Uveal Diseases Eye Diseases Cyclooxygenase Inhibitors Diclofenac Retinal Degeneration Macular Degeneration Enzyme Inhibitors Triamcinolone diacetate Immunosuppressive Agents Glucocorticoids Pharmacologic Actions Analgesics, Non-Narcotic |